Market Overview

Pete Najarian Sees Unusual Options Activity In SPDR S&P Biotech

Related XBI
19 Biotech Stocks With Clinical Trial Outcomes In February
Attention Biotech Investors: February PDUFA Catalysts Come Calling
The Next Immuno-Oncology Frontier? (Seeking Alpha)

On CNBC's "Fast Money Halftime Report", Pete Najarian spoke about high options volume in SPDR S&P Biotech (ETF) (NYSE: XBI).

He said that around 22,000 contracts of the November 90 calls were bought for $2. It's unusual to see that much volume in SPDR S&P Biotech, explained Najarian. The trade breaks even at $92 or 4.26 percent above the current market price. Najarian decided to follow the trade.

Posted-In: Fast Money Halftime Report Pete NajarianCNBC Options Markets Media ETFs


Related Articles (XBI)

View Comments and Join the Discussion!